Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
First and only approved treatment in China for rare and progressive genetic condition, which can result in growth of benign tumours along nerves throughout the body. Results from pivotal SPRINT trial showed Koselugo reduced tumour volume, with potential to ease pain, functional impairment and other clinical complications.Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. The approval by the National Medical Products